• Explore /
  • Poster
  • / Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Abstract Video & Slides Poster

Authors

William Tap

William D. Tap

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

William D. Tap , Andrew J. Wagner , Sebastian Bauer , Michael C. Heinrich , Robin Lewis Jones , Cesar Serrano , Margaret von Mehren , Neeta Somaiah , Tom Andor , Liangxing Zou , Ben Exter , Julia Lawrence , Celeste LaHaie , Shaunica Mitchell , Kevin Moynihan , Jessica Sachs , Lei Sun , Jonathan C. Trent

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT05208047

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11537)

DOI

10.1200/JCO.2023.41.16_suppl.11537

Abstract #

11537

Poster Bd #

471

Abstract Disclosures

Similar Posters

First Author: Suzanne George

First Author: Andrew J. Wagner

First Author: Michael C. Heinrich

First Author: Hidekazu Hirano